12:00 AM
 | 
Aug 02, 2004
 |  BC Week In Review  |  Company News  |  Other News

Inflazyme autoimmune, inflammation news

IZP restructured its R&D efforts to focus on its Complement Inhibition and Prodaptin technologies. The company will reduce its headcount by 42, or about half, to 40. Positions will be...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >